Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
BDNF has been linked to the pathogenesis of airway hyperresponsiveness in asthma. In this trial, the impact of a treatment with salmeterol and salmeterol / fluticasone on BDNF concentrations will be assessed in patients with asthma. The investigators hypothesize that salmeterol impacts on BDNF concentrations in patients with asthma.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
|Official Title:||Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma|
- BDNF concentrations in serum, platelets and plasma [ Time Frame: 2006 - 2007 ] [ Designated as safety issue: No ]
- Airway hyperresponsiveness [ Time Frame: 2006 - 2007 ] [ Designated as safety issue: No ]
|Study Start Date:||September 2005|
|Study Completion Date:||April 2007|
|Primary Completion Date:||January 2007 (Final data collection date for primary outcome measure)|
Treatment with Salmeterol for 2 weeks, followed by a treatment with Salmeterol and Fluticasone for 2 weeks.
Drug: Salmeterol and Salmeterol / Fluticasone
Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00736801
|University of Rostock|
|Rostock, Germany, 18057|
|Study Chair:||Johann C. Virchow, MD, FCCP||University of Rostock|